Tradestie Institutional Equity Comparison Engine

STLN vs XLO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

XLO Overall Edge

XLO Captures Institutional Edge (3โ€“0 Pillars ยท 8โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Xilio Therapeutics, Inc. Common Stock (XLO) driven by superior Valuation, Growth & Margin, Momentum & Technical. Fundamentally, STLN trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus XLO at N/M Forward P/E and -74.9% operating margin (-47.6% YoY). In options structure, STLN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against XLO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner XLO
STLN N/M vs XLO N/M Fwd P/E
Growth & Margin Winner XLO
Op Margin N/A vs -74.9% ยท YoY N/A vs -47.6%
Momentum & Technical Winner XLO
1Y -42.0% vs +836.8% ยท 52W Pos 1% vs 75%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
STLN US Equity
STLN
Institutional Equity
$3.00
-5.66% 1D
Market Cap N/A
1M Return -56.58%
1Y Return -41.97%
Forward P/E N/M
Unified AI Score
46.6 / 100 HOLD
Tech 45.0 Fund 46.0 Flow 50.0 Mom 55.0
XLO NASDAQ
Xilio Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$7.56
+0.67% 1D
Market Cap $53.1M
1M Return -5.85%
1Y Return +836.8%
Forward P/E N/M
Unified AI Score
45.8 / 100 HOLD
Tech 40.0 Fund 50.0 Flow 50.0 Mom 74.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: STLN -41.97% XLO +836.8% Spread: +25.14 pp (XLO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
STLN TTM Op. Margin: N/A XLO TTM Op. Margin: -74.9%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on STLN vs XLO. Trailing 12-month operating profitability (STLN N/A vs XLO -74.9%) and valuation multiples (STLN N/M vs XLO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: STLN (1) vs XLO (8)
Institutional Metric STLN XLO Criterion Row Winner
Market Capitalization Scale N/A $53.1M Larger Scale XLO
Trailing P/E Ratio Valuation N/M 11.6x Lower Multiple XLO
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A -47.6% Higher Growth XLO
Operating Margin (TTM) Profitability N/A -74.9% Higher Margin XLO
Net Profit Margin Profitability N/A -20.9% Higher Margin XLO
Return on Equity (ROE) Capital Efficiency N/A -38.2% Higher ROE XLO
52-Week Range Position Momentum 1% ($3โ€“$7) 75% ($0โ€“$10) Stronger Trend XLO
Beta / 30D Volatility Risk Regime 1.42ฮฒ ยท 175% Vol 0.74ฮฒ ยท 63% Vol Lower Realized Risk XLO
Unified Institutional Score Composite Signal 46.6 / 100 (HOLD) 45.8 / 100 (HOLD) Higher Composite STLN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full STLN vs XLO Buy Guide
STLN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live STLN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
XLO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live XLO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither STLN nor XLO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.